How LUTATHERA May Help

Clinical Trial Results for LUTATHERA

In a clinical trial, 229 people with midgut NETs who received LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use in combination with 30 mg of long-acting octreotide were compared with those who received 60 mg of long-acting octreotide alone.

Longer Progression-Free Survival (PFS) for Patients Treated With LUTATHERA

In the LUTATHERA group, the relative risk of the cancer getting worse or death was reduced by 79% compared with people treated with 60 mg of long-acting octreotide alone.
79%
 

 

More people treated with LUTATHERA had their tumors shrink compared with people treated with 60 mg of long-acting octreotide alone

13% of people
in the LUTATHERA plus 30 mg of long-acting octreotide group

 

Partial response (tumors shrink)a:
12% (14 of 116 people)

Complete response (tumors disappear)b:
1% (1 of 116 people)

4% of people
in the 60 mg of long-acting octreotide group

 

Partial response (tumors shrink)a:
4% (4 of 113 people)

Complete response (tumors disappear)b:
0% (0 of 113 people)

aTumors shrink to ≥30% from baseline.

bTumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.